{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Slingluff CL"],"funding":["NCRR NIH HHS","NCI NIH HHS"],"pagination":["2924-32"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC3138719"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["29(21)"],"pubmed_abstract":["Purpose
This multicenter randomized trial was designed to test whether melanoma-associated helper peptides augment CD8(+) T-cell responses to a melanoma vaccine and whether cyclophosphamide (CY) pretreatment augments CD4(+) or CD8(+) T-cell responses to that vaccine.Patients and methods
In all, 167 eligible patients with resected stage IIB to IV melanoma were randomly assigned to four vaccination study arms. Patients were vaccinated with 12 class I major histocompatibility complex-restricted melanoma peptides (12MP) to stimulate CD8(+) T cells and were randomly assigned to receive a tetanus helper peptide or a mixture of six melanoma-associated helper peptides (6MHP) to stimulate CD4(+) T cells. Before vaccination, patients were also randomly assigned to receive CY pretreat"],"journal":["Journal of clinical oncology : official journal of the American Society of Clinical Oncology"],"pubmed_title":["Randomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccine."],"pmcid":["PMC3138719"],"funding_grant_id":["M01 RR000847","P30 CA44579","R01 CA118386","M01 RR00847","P30 CA044579"],"pubmed_authors":["von Mehren M","Chianese-Bullock KA","Smolkin ME","Haas NB","Ross MI","Petroni GR","Slingluff CL","Grosh WW"],"additional_accession":[]},"is_claimable":false,"name":"Randomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccine.","description":"Purpose
This multicenter randomized trial was designed to test whether melanoma-associated helper peptides augment CD8(+) T-cell responses to a melanoma vaccine and whether cyclophosphamide (CY) pretreatment augments CD4(+) or CD8(+) T-cell responses to that vaccine.Patients and methods
In all, 167 eligible patients with resected stage IIB to IV melanoma were randomly assigned to four vaccination study arms. Patients were vaccinated with 12 class I major histocompatibility complex-restricted melanoma peptides (12MP) to stimulate CD8(+) T cells and were randomly assigned to receive a tetanus helper peptide or a mixture of six melanoma-associated helper peptides (6MHP) to stimulate CD4(+) T cells. Before vaccination, patients were also randomly assigned to receive CY pretreat","dates":{"release":"2011-01-01T00:00:00Z","publication":"2011 Jul","modification":"2026-05-04T18:39:02.455Z","creation":"2019-03-26T23:49:33Z"},"accession":"S-EPMC3138719","cross_references":{"pubmed":["21690475"],"doi":["10.1200/jco.2010.33.8053","10.1200/JCO.2010.33.8053"]}}